Tandem Diabetes 2021 results, 2022 guidance

 2021 FINANCIAL HIGHLIGHTS

In comparing the year ended December 31, 2021 to the same period of 2020:

• Sales increased 41 percent to $702.8 million

• Worldwide pump shipments increased 41 percent to 128,312 pumps

• Gross margin improved 2 percentage points to 54 percent of sales

• Achieved positive annual operating margin

• Adjusted EBITDA(1) increased to 14 percent of sales

2022 Financial Guidance

For the year ending December 31, 2022, the Company is providing financial guidance as follows:

• Sales are estimated to be in the range of $845 million to $860 million, which represents an annual sales growth of 20% percent to 22% percent compared to 2021

  • Includes sales outside the United States of approximately $215 million to $220 million

• Gross margin is estimated to be approximately 54 percent

• Adjusted EBITDA(1) is estimated to be in the range of 14 percent to 15 percent of sales

• Non-cash charges included in cost of goods sold and operating expenses are estimated to be approximately $90 million, which include:

• Approximately $75 million non-cash, stock-based compensation expense

• Approximately $15 million depreciation and amortization expense

• https://finance.yahoo.com/news/tandem-diabetes-care-announces-fourth-210500974.html